Adar Poonawalla, CEO of SII said preliminary results have shown that there are no immediate concerns pertaining to the Covishield vaccine. A total of 1600 people have been administered the first dose across 17 sites, and each participant is being followed up for six months to ensure safety of the vaccine.
CEO of Serum Institute of India, Adar Poonawalla.
The phase 2/3 human clinical trial for a vaccine against coronavirus has been running smoothly in the country with no safety concerns so far, and the entire recruitment process of 1,600 volunteers for the Covishield vaccine trial has been completed across 17 trial sites by October 31, according to the Serum Institute of India (SII).
Serum Institute, the world’s largest vaccine manufacturer by the number of doses produced, is working on several candidates for a vaccine against Covid-19, including one from AstraZeneca-Oxford University as well as developing its own.
Stating that there are no safety concerns related to the Covishield vaccine trial, SII’s CEO, Adar Poonawalla, said, “It is too early to comment on the vaccine’s availability, or the (chances of) trial completion by December 2020.”
There are more than 83 lakh reported cases of Covid-19 and over 1.23 lakh deaths recorded across the country until now, and the rollout of the vaccine may take a few months.
Poonawalla said: “Preliminary results have shown that there are no immediate concerns pertaining to the Covishield vaccine. So far, thousands of people have had it in India and abroad with no safety concerns.”
Poonawalla said prioritising the vaccine’s distribution lies with government agencies and the Health Ministry, but it is “likely” that frontline workers and young and old adults will be on the priority list.
He said that based on some initial reports of the trials in the UK, the AstraZeneca-Oxford vaccine has shown immune response. “However, it is too early and is dependent on trial’s success in proving the vaccine immunogenic and efficacious,” he said in an email interview with The Indian Express.
From the first volunteer for the Covishield trial enrolled on August 24 to a total of 1,600 recruited by October 31, each person has been administered the first dose across 17 sites, and each participant is being followed up for six months to ensure safety of the vaccine.
There are a few sites that are part of the immunogenicity cohort where participants are being randomly assigned in a 3:1 ratio to receive either Covishield or Oxford/AZ-ChAdOx1 nCov 19, respectively. The remaining 1,200 participants from the safety cohort are being randomly assigned in a 3:1 ratio to receive either Covishield or Placebo, respectively.
At some sites, several volunteers have received the second dose as part of the phase 2/3 observer blind, randomised, controlled study to determine the safety and immunogenicity of Covishield vaccine in healthy Indian adults.
The SII chief said that doses will be allocated proportionally across 92 countries in the COVAX AMC (Advance Market Commitment) and in accordance with WHO’s global allocation framework, which is currently under development. “As part of the alliance with GAVI and Gates Foundation, we will deliver 200 mn [million] doses of AstraZeneca-Oxford and Novavax vaccines in 67 and 92 countries, respectively,” Poonawalla said.
“As per our current agreement with AstraZeneca, GAVI Alliance, and the Gates Foundation, the vaccines will be distributed through them and as part of government immunisation programmes (once proven immunogenic) to low and middle-income countries (GAVI countries) and India,” Poonawalla said.
Source - The Indian Express
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.